Cathie Wood Dumps Palantir As Stock Touches Peak Prices, Bails On Soaring Flying-Taxi Maker Archer Aviation
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today
Illumina Analysts Lower Their Forecasts After Q1 Results
Biomarin Pharma Announces New VOXZOGO Data Showing Tibial Bowing Improvement In Achondroplasia
'Trump To Sign Order To Cut Some U.S. Drug Prices To Match Those Abroad' - CNBC
Canaccord Genuity Maintains Hold on Illumina, Lowers Price Target to $87
Alnylam Pharma To Present Latest Data From Flagship Transthyretin Amyloidosis Franchise At Upcoming Heart Failure 2025 Congress
Notable Healthcare Headlines for the Week: Viatris, Novavax and UnitedHealth in Focus
Trump Says 'GREAT PROGRESS MADE' at U.S.-China Trade Talks, Which Will Resume Sunday
Bio-Techne Analyst Ratings
10 Health Care Stocks With Whale Alerts In Today's Session
Illumina Analyst Ratings
Ultragenyx Pharmaceutical Analyst Ratings
8 Analysts Have This To Say About Natera
Natera Analyst Ratings
Chardan Capital Maintains Buy on Avidity Biosciences, Maintains $65 Price Target
Avidity Biosciences Analyst Ratings
Illumina Outlines $4.18B to $4.26B Guidance for 2025 Amid China Headwinds and Strategic Cost Reductions
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Avidity Biosciences Q1 EPS $(0.90) Beats $(0.91) Estimate, Sales $1.57M Miss $1.90M Estimate